Document is current
Any future updates will be listed below
-
Authors
Holmstroem, Rikke Boedker https://orcid.org/0000-0002-5476-9937
Teisner, Ane Soegaard
Sweep, Mark Wilhelmus Dirk https://orcid.org/0000-0002-3080-8903
Noringriis, Inge Mansfield https://orcid.org/0000-0001-7802-2099
Khan, Shawez https://orcid.org/0000-0003-1682-4824
Aagaard, Niels Kristian
Karlström, Jacob
Jurlander, Rebecca Schou
Sohlin, Joel E
Monberg, Tine Juul https://orcid.org/0000-0002-7217-2974
Vestergaard, Cecilie
Stoltenborg Granhøj, Joachim
Stenbøg, Poul
Toxvaerd, Anders
Hansen, Alastair B
Bjerring, Peter Nissen https://orcid.org/0000-0001-8636-0709
Lorentzen, Torben
Thielsen, Peter
Bol, Kalijn https://orcid.org/0000-0003-4165-2040
Jonsson, Goran https://orcid.org/0000-0001-6865-0147
Ellebaek, Eva
Svane, Inge Marie https://orcid.org/0000-0002-9451-6037
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04810156 at ClinicalTrials.govnct04810156 at ClinicalTrials.govDocuments that mention this clinical trial
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
https://doi.org/10.1136/jitc-2025-013861
Documents that mention this clinical trial
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
https://doi.org/10.1136/jitc-2025-013861
-
Funding
Funding for this research was provided by:
Novo Nordisk Foundation (NNF21OC0067432)
Sundhedsdonationer Sygeforsikring Danmark (2020-0253)
Sundhedsstyrelsen (05-0400-18)
Sundhedsstyrelsen (05-0400-50)
- License Information
